Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fludarabine
Drug ID BADD_D00914
Description Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
Indications and Usage For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
Marketing Status approved
ATC Code L01BB05
DrugBank ID DB01073
KEGG ID D07966
MeSH ID C024352
PubChem ID 657237
TTD Drug ID D0F2XQ
NDC Product Code 16729-131
UNII P2K93U8740
Synonyms fludarabine | 9H-purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- | F-ara-A | 2-fluoroadenine arabinoside | 9-beta-D-arabinofuranosyl-2-fluoroadenine
Chemical Information
Molecular Formula C10H12FN5O4
CAS Registry Number 21679-14-1
SMILES C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diffuse large B-cell lymphoma recurrent16.28.02.002; 01.15.02.0020.000112%Not Available
Richter's syndrome16.28.02.005; 01.15.02.0050.000336%Not Available
Metastatic squamous cell carcinoma16.16.01.0100.000112%Not Available
Acute lymphocytic leukaemia recurrent16.01.01.003; 01.10.01.0030.000280%Not Available
Graft versus host disease in skin23.07.04.025; 12.02.09.031; 10.02.01.0620.000224%Not Available
Graft versus host disease in liver12.02.09.029; 10.02.01.060; 09.01.07.0330.000112%Not Available
Clonal evolution16.32.03.0220.000112%Not Available
Acute graft versus host disease in skin23.07.04.020; 12.02.09.022; 10.02.01.0530.000168%Not Available
Invasive lobular breast carcinoma21.05.01.022; 16.10.01.0140.000112%Not Available
Graft versus host disease in gastrointestinal tract07.11.01.027; 12.02.09.028; 10.02.01.0590.000280%Not Available
Toxic leukoencephalopathy17.13.02.012; 12.03.01.0590.000839%Not Available
Ductal adenocarcinoma of pancreas16.13.10.006; 07.21.09.0110.000112%Not Available
Haemophagocytic lymphohistiocytosis16.32.03.038; 10.02.01.077; 01.05.01.0260.000839%Not Available
Hypersensitivity pneumonitis22.01.01.027; 10.01.03.056--Not Available
Immune effector cell-associated neurotoxicity syndrome19.13.01.006; 17.13.01.015; 12.03.01.0650.000168%Not Available
Immune thrombocytopenia10.02.01.083; 01.08.01.0130.000224%Not Available
Juvenile chronic myelomonocytic leukaemia01.10.07.005; 16.01.07.0050.000112%Not Available
Malignant neoplasm of unknown primary site16.16.01.0190.000112%Not Available
Paraneoplastic pemphigus23.03.01.040; 16.32.01.013; 10.04.02.0200.000112%Not Available
Therapy non-responder08.06.01.0630.000616%Not Available
The 9th Page    First    Pre   9    Total 9 Pages